Trial Profile

A Phase 1, Open-label, Dose-escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of NOV1601(CHC2014) in Adult Subjects With Solid Organ Malignancies

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AUM 601 (Primary)
Indications Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Solid tumours; Uterine cancer
Focus Adverse reactions; First in man
Sponsors National OncoVenture

Most Recent Events

19 Apr 2022 According to a AUM Biosciences media release, results from this trial were presented at the ESMO Targeted Anticancer Congress 2022.
08 Mar 2022 Results presented at the 20th International Congress on Targeted Anticancer Therapies
08 Sep 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com